Tahani Alshehri

Tahani Alshehri

Auto-generated profile, based on publicly available information

Tahani Alshehri

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Biological Psychiatry
Verified
Journal Article
Closed access
MBMariska Bot
Mariska Bot
YMYuri Milaneschi
Yuri Milaneschi
TATahani Al-Shehri
Tahani Al-Shehri
NANajaf Amin
Najaf Amin
SGSanzhima Garmaeva
Sanzhima Garmaeva
NSN. Sattar
N. Sattar

13 June 2019 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
HDHassan S. Dashti
Hassan S. Dashti
JMJordi Merino
Jordi Merino
JLJacqueline M Lane
Jacqueline M Lane
YSYanwei Song
Yanwei Song
CSCaren E Smith
Caren E Smith
RSRicha Saxena
Richa Saxena
Little is known about the contribution of genetic variation to food timing, and breakfast has been determined to exhibit the most heritable meal timing. As breakfast timing and skipping are not routinely measured in large cohort studies, alternative approaches include analyses of correlated traits. The aim of this study was to elucidate breakfast skipping genetic variants through a proxy-phenotype genome-wide association study (GWAS) for breakfast cereal skipping, a commonly assessed correlated trait. We leveraged the statistical power of the UK Biobank (n = 193,860) to identify genetic variants related to breakfast cereal skipping as a proxy-phenotype for breakfast skipping and applied several in silico approaches to investigate mechanistic functions and links to traits/diseases. Next, we attempted validation of our approach in smaller breakfast skipping GWAS from the TwinUK (n = 2,006) and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium (n = 11,963). In the UK Biobank, we identified 6 independent GWAS variants, including those implicated for caffeine (ARID3B/CYP1A1), carbohydrate metabolism (FGF21), schizophrenia (ZNF804A), and encoding enzymes important for N6-methyladenosine RNA transmethylation (METTL4, YWHAB, and YTHDF3), which regulates the pace of the circadian clock. Expression of identified genes was enriched in the cerebellum. Genome-wide correlation analyses indicated positive correlations with anthropometric traits. Through Mendelian randomization (MR), we observed causal links between genetically determined breakfast skipping and higher body mass index, more depressive symptoms, and smoking. In bidirectional MR, we demonstrated a causal link between being an evening person and skipping breakfast, but not vice versa. We observed association of our signals in an independent breakfast skipping GWAS in another British cohort (P = 0.032), TwinUK, but not in a meta-analysis of non-British cohorts from the CHARGE consortium (P = 0.095). Our proxy-phenotype GWAS identified 6 genetic variants for breakfast skipping, linking clock regulation with food timing and suggesting a possible beneficial role of regular breakfast intake as part of a healthy lifestyle.

1 December 2019 in Psychoneuroendocrinology
Verified
Journal Article
Open access
TATahani Alshehri
Tahani Alshehri
SBSebastiaan Boone
Sebastiaan Boone
RMRenée de Mutsert
Renée de Mutsert
BPBrenda Penninx
Brenda Penninx
FRFrits Rosendaal
Frits Rosendaal
DKDennis Mook- Kanamori
Dennis Mook- Kanamori
We aimed to evaluate the association between measures of adiposity with depressive mood and specific depressive symptoms. This study was performed in the Netherlands Epidemiology of Obesity (NEO) study, a population-based study that consists of 6671 middle-aged individuals. We examined the association between measures of overall adiposity (BMI and total body fat), and abdominal adiposity (waist circumference and visceral adipose tissue), with depressive mood severity subgroups and 30 depressive symptoms. Multinomial logistic regression was performed adjusting for potential confounding. Measures of adiposity were associated with depressive mood in a graded fashion. Total body fat showed the strongest association with mild (Odds Ratio (OR): 1.59 per standard deviation, 95% Confidence Interval (95% CI): 1.41-1.80) and moderate to very severe (OR: 1.97, 95% CI: 1.59-2.44) depressive mood. Regarding individual symptoms of depressive mood, total body fat was associated with most depressive symptoms (strongest associations for hyperphagia and fatigability). In the general population, overall and abdominal adiposity measures were associated with depressive mood. This association encompasses most of the depressive symptoms and appeared to be the strongest with specific ''atypical'' neurovegetative symptoms, which may be an indication of an alteration in the energy homeostasis.

3 June 2021 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
TATahani Alshehri
Tahani Alshehri
DKDennis O. Mook- Kanamori
Dennis O. Mook- Kanamori
KDKo Willems van Dijk
Ko Willems van Dijk
RDRichard Dinga
Richard Dinga
BPBrenda W. J. H. Penninx
Brenda W. J. H. Penninx
YMYuri Milaneschi
Yuri Milaneschi
Background: A recent hypothesis postulates the existence of an ‘immune-metabolic depression’ (IMD) dimension characterized by metabolic dysregulations. Combining data on metabolomics and depressive symptoms, we aimed to identify depressions associated with an increased risk of adverse metabolic alterations.Method: Clustering data were from 1094 individuals with major depressive disorder in the last 6 months and measures of 149 metabolites from a 1H-NMR platform and 30 depressive symptoms (IDS-SR30). Canonical correlation analyses (CCA) were used to identify main independent metabolite-symptom axes of variance. Then, for the replication, we examined the association of the identified dimensions with metabolites from the same platform and cardiometabolic diseases in an independent population-based cohort (n = 6572).Results: CCA identified an overall depression dimension and a dimension resembling IMD, in which symptoms such as sleeping too much, increased appetite, and low energy level had higher relative loading. In the independent sample, the overall depression dimension was associated with lower cardiometabolic risk, such as (i.e. per s.d.) HOMA-1B −0.06 (95% CI −0.09 – −0.04), and visceral adipose tissue −0.10 cm2 (95% CI −0.14 – −0.07). In contrast, the IMD dimension was associated with well-known cardiometabolic diseases such as higher visceral adipose tissue 0.08 cm2 (95% CI 0.04–0.12), HOMA-1B 0.06 (95% CI 0.04–0.09), and lower HDL-cholesterol levels −0.03 mmol/L (95% CI −0.05 – −0.01).Conclusions: Combining metabolomics and clinical symptoms we identified a replicable depression dimension associated with adverse metabolic alterations, in line with the IMD hypothesis. Patients with IMD may be at higher cardiometabolic risk and may benefit from specific treatment targeting underlying metabolic dysregulations.

6 December 2022 in Brain, Behavior, and Immunity
Verified
Journal Article
Open access
TATahani Alshehri
Tahani Alshehri
DMDennis O Mook-Kanamori
Dennis O Mook-Kanamori
RMRenée de Mutsert
Renée de Mutsert
BPBrenda Wjh Penninx
Brenda Wjh Penninx
FRFrits R Rosendaal
Frits R Rosendaal
YMYuri Milaneschi
Yuri Milaneschi
Adiposity has been shown to be linked with atypical energy-related symptoms (AES) of depression. We used genomics to separate the effect of adiposity from that of metabolic dysregulations to examine whether the link between obesity and AES is dependent on the presence of metabolic dysregulations. Data were from NEO (n = 5734 individuals) and NESDA (n = 2238 individuals) cohorts, in which the Inventory of Depressive Symptomatology (IDS-SR30) was assessed. AES profile was based on four symptoms: increased appetite, increased weight, low energy level, and leaden paralysis. We estimated associations between AES and two genetic risk scores (GRS) indexing increasing total body fat with (metabolically unhealthy adiposity, GRS-MUA) and without (metabolically healthy adiposity, GRS-MHA) metabolic dysregulations. We validated that both GRS-MUA and GRS-MHA were associated with higher total body fat in NEO study, but divergently associated with biomarkers of metabolic health (e.g., fasting glucose and HDL-cholesterol) in both cohorts. In the pooled results, per standard deviation, GRS-MUA was specifically associated with a higher AES score (β = 0.03, 95%CI: 0.01; 0.05), while there was no association between GRS-MHA and AES (β = -0.01, 95%CI: -0.03; 0.01). These results suggest that the established link between adiposity and AES profile emerges in the presence of metabolic dysregulations, which may represent the connecting substrate between the two conditions.

11 August 2020 in medRxiv
Verified
Preprint
Open access
PDF file
TATahani Alshehri
Tahani Alshehri
DMDennis O Mook-Kanamori
Dennis O Mook-Kanamori
KDKo Willems van Dijk
Ko Willems van Dijk
RDRichard Dinga
Richard Dinga
BPBrenda Wjh Penninx
Brenda Wjh Penninx
YMYuri Milaneschi
Yuri Milaneschi
Background: A recent hypothesis postulates the existence of an “immune-metabolic depression” (IMD) dimension characterized by metabolic dysregulations. Combining data on metabolomics and depressive symptoms, we aimed to identify depressions associated with an increased risk of adverse metabolic alterations. Method: Clustering data were from 1094 individuals with current major depressive disorder and measures of 149 metabolites from a 1 H-NMR platform and 30 depressive symptoms (IDS-SR30). Canonical correlation analyses (CCA) were used to identify main independent metabolite-symptom axes of variance. Then, for the replication, we examined the association of the identified dimensions with metabolites from the same platform and cardiometabolic endpoints in an independent population-based cohort (n=6572). Results: CCA identified an overall depression dimension and a dimension resembling IMD, in which symptoms such as sleeping too much, increased appetite, and low energy level had higher relative loading. In the independent sample, the overall depression dimension was associated with lower levels of metabolites linked to cardiometabolic risk, such as HOMA-1B −0.09 (95% CI:-0.13--0.06), and visceral adipose tissue −0.15 cm 2 (95% CI:-0.20--0.10). In contrast, the IMD dimension was associated with well-known adverse cardiometabolic metabolites such as higher visceral adipose tissue 0.11 cm 2 (95% CI:0.06-0.16), HOMA-1B 0.08 (95% CI: 0.05-0.12), and lower HDL levels −0.04 mmol/L (95% CI:-0.07--0.01). Conclusions: Combining metabolomics and clinical symptoms we identified a replicable depression dimension associated with adverse metabolic alterations, in line with the IMD hypothesis. Patients with IMD may be at higher cardiometabolic risk and may benefit from specific treatment targeting underlying metabolic dysregulations.